BioCryst’s BCX4161 receives FDA fast-track designation to treat HAE | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« 2:00PM–5:00PM, January 27, 2015 – Personalizing Evidence in the Learning Healthcare System & Biomarker Discovery Technologies, LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA

8:30AM–12:00PM, January 28, 2015 – Morality, Ethics & Public Law in PM, LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA »

BioCryst’s BCX4161 receives FDA fast-track designation to treat HAE

January 28, 2015 by larryhbern

Posted in Uncategorized | Leave a Comment

Leave a ReplyCancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,330 other subscribers
Recent Posts
- The Future of AI in Cardiology November 5, 2023
- Overview of Alzheimer’s Disease and Novel Treatments Targeting Beta-Amyloid Deposits October 7, 2023
- The Implications and Association of Stair Climbing with Atherosclerotic Cardiovascular Disease (ASCVD) October 6, 2023
- The Nobel Prize in Physiology or Medicine 2023 October 2, 2023
- The Current Impact and Future of Technology within Cardiovascular Surgery September 23, 2023
- The Continued Impact and Possibilities of AI in Medical and Pharmaceutical Industry Practices September 18, 2023
- Regulatory T cells (Tregs) are important for sperm tolerance and male fertility September 11, 2023
- ChatGPT Chemistry Assistant for Text Mining and the Prediction of metal–organic framework (MOF) synthesis August 27, 2023
- Eight Subcellular Pathologies driving Chronic Metabolic Diseases – Methods for Mapping Bioelectronic Adjustable Measurements as potential new Therapeutics: Impact on Pharmaceuticals in Use August 19, 2023
- ChatGPT Searches and Advent of Meta Threads: What it Means for Social Media and Science 3.0 July 11, 2023
Archives
Archives
Categories
Categories
Meta

%d